{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,29]],"date-time":"2026-07-29T23:59:15Z","timestamp":1785369555605,"version":"3.55.0"},"reference-count":39,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","theclinics.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Endocrinology and Metabolism Clinics of North America"],"published-print":{"date-parts":[[2026,9]]},"DOI":"10.1016\/j.ecl.2026.04.010","type":"journal-article","created":{"date-parts":[[2026,5,18]],"date-time":"2026-05-18T11:20:49Z","timestamp":1779103249000},"page":"455-466","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["GLP-1 Receptor Agonists May Reduce Insulin Requirements in New-Onset Type 1 Diabetes"],"prefix":"10.1016","volume":"55","author":[{"given":"Justin M.","family":"Gregory","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"10","key":"10.1016\/j.ecl.2026.04.010_bib1","doi-asserted-by":"crossref","first-page":"958","DOI":"10.1056\/NEJMc2302677","article-title":"Semaglutide in early type 1 diabetes","volume":"389","author":"Dandona","year":"2023","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ecl.2026.04.010_bib2","author":"Scott"},{"issue":"3","key":"10.1016\/j.ecl.2026.04.010_bib4","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1056\/NEJMc2311608","article-title":"More on semaglutide in early type 1 diabetes","volume":"390","author":"DeVries","year":"2024","journal-title":"N Engl J Med"},{"issue":"3","key":"10.1016\/j.ecl.2026.04.010_bib5","first-page":"291","article-title":"More on semaglutide in early type 1 diabetes","volume":"390","author":"Weinrauch","year":"2024","journal-title":"N Engl J Med"},{"issue":"3","key":"10.1016\/j.ecl.2026.04.010_bib6","first-page":"291","article-title":"More on semaglutide in early type 1 diabetes","volume":"390","author":"Gaglia","year":"2024","journal-title":"N Engl J Med"},{"issue":"9862","key":"10.1016\/j.ecl.2026.04.010_bib7","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1016\/S0140-6736(13)60079-3","article-title":"George Stephen Eisenbarth","volume":"381","author":"Watts","year":"2013","journal-title":"Lancet"},{"issue":"3","key":"10.1016\/j.ecl.2026.04.010_bib8","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1007\/s00125-013-2833-0","article-title":"1947-2012","volume":"56","author":"Atkinson","year":"2013","journal-title":"Diabetologia"},{"issue":"26","key":"10.1016\/j.ecl.2026.04.010_bib9","doi-asserted-by":"crossref","first-page":"2849","DOI":"10.1056\/NEJMc0805398","article-title":"Concordance for islet autoimmunity among monozygotic twins","volume":"359","author":"Redondo","year":"2008","journal-title":"N Engl J Med"},{"issue":"8","key":"10.1016\/j.ecl.2026.04.010_bib10","doi-asserted-by":"crossref","first-page":"717","DOI":"10.2337\/diab.33.8.717","article-title":"Pre-type I diabetes. Linear loss of beta cell response to intravenous glucose","volume":"33","author":"Srikanta","year":"1984","journal-title":"Diabetes"},{"issue":"21","key":"10.1016\/j.ecl.2026.04.010_bib11","doi-asserted-by":"crossref","first-page":"1360","DOI":"10.1056\/NEJM198605223142106","article-title":"Type I diabetes mellitus. A chronic autoimmune disease","volume":"314","author":"Eisenbarth","year":"1986","journal-title":"N Engl J Med"},{"issue":"10","key":"10.1016\/j.ecl.2026.04.010_bib12","doi-asserted-by":"crossref","first-page":"1964","DOI":"10.2337\/dc15-1419","article-title":"Staging presymptomatic type 1 diabetes: a scientific statement of JDRF, the Endocrine Society, and the American Diabetes Association","volume":"38","author":"Insel","year":"2015","journal-title":"Diabetes Care"},{"issue":"3","key":"10.1016\/j.ecl.2026.04.010_bib13","doi-asserted-by":"crossref","first-page":"643","DOI":"10.2337\/diacare.29.03.06.dc05-1006","article-title":"Patterns of metabolic progression to type 1 diabetes in the Diabetes prevention trial-type 1","volume":"29","author":"Sosenko","year":"2006","journal-title":"Diabetes Care"},{"issue":"2","key":"10.1016\/j.ecl.2026.04.010_bib14","doi-asserted-by":"crossref","first-page":"426","DOI":"10.2337\/diabetes.53.2.426","article-title":"Insulin secretion in type 1 diabetes","volume":"53","author":"Steele","year":"2004","journal-title":"Diabetes"},{"issue":"11","key":"10.1016\/j.ecl.2026.04.010_bib15","doi-asserted-by":"crossref","first-page":"876","DOI":"10.1177\/106002808902301108","article-title":"Acute hypotensive reaction to etoposide with successful rechallenge: case report and review of the literature","volume":"23","author":"Cersosimo","year":"1989","journal-title":"DICP"},{"issue":"7","key":"10.1016\/j.ecl.2026.04.010_bib16","doi-asserted-by":"crossref","first-page":"1403","DOI":"10.2337\/dc08-0575","article-title":"Too much glucagon, too little insulin: time course of pancreatic islet dysfunction in new-onset type 1 diabetes","volume":"31","author":"Brown","year":"2008","journal-title":"Diabetes Care"},{"issue":"6","key":"10.1016\/j.ecl.2026.04.010_bib17","doi-asserted-by":"crossref","first-page":"1741","DOI":"10.2337\/dc13-2612","article-title":"Evolution of abnormal plasma glucagon responses to mixed-meal feedings in youth with type 1 diabetes during the first 2 years after diagnosis","volume":"37","author":"Sherr","year":"2014","journal-title":"Diabetes Care"},{"issue":"7","key":"10.1016\/j.ecl.2026.04.010_bib18","doi-asserted-by":"crossref","first-page":"1463","DOI":"10.2337\/dc11-0096","article-title":"Four weeks of treatment with liraglutide reduces insulin dose without loss of glycemic control in type 1 diabetic patients with and without residual beta-cell function","volume":"34","author":"Kielgast","year":"2011","journal-title":"Diabetes Care"},{"issue":"4","key":"10.1016\/j.ecl.2026.04.010_bib19","doi-asserted-by":"crossref","first-page":"470","DOI":"10.1124\/pr.108.000604","article-title":"The role of incretins in glucose homeostasis and diabetes treatment","volume":"60","author":"Kim","year":"2008","journal-title":"Pharmacol Rev"},{"issue":"2","key":"10.1016\/j.ecl.2026.04.010_bib20","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1210\/jcem-63-2-492","article-title":"Incretin effects of increasing glucose loads in man calculated from venous insulin and C-peptide responses","volume":"63","author":"Nauck","year":"1986","journal-title":"J Clin Endocrinol Metab"},{"issue":"4","key":"10.1016\/j.ecl.2026.04.010_bib21","first-page":"912","article-title":"Additive insulinotropic effects of exogenous synthetic human gastric inhibitory polypeptide and glucagon-like peptide-1-(7-36) amide infused at near-physiological insulinotropic hormone and glucose concentrations","volume":"76","author":"Nauck","year":"1993","journal-title":"J Clin Endocrinol Metab"},{"issue":"4","key":"10.1016\/j.ecl.2026.04.010_bib22","doi-asserted-by":"crossref","first-page":"951","DOI":"10.2337\/diabetes.51.4.951","article-title":"Impaired beta-cell function, incretin effect, and glucagon suppression in patients with type 1 diabetes who have normal fasting glucose","volume":"51","author":"Greenbaum","year":"2002","journal-title":"Diabetes"},{"issue":"12","key":"10.1016\/j.ecl.2026.04.010_bib23","doi-asserted-by":"crossref","first-page":"2189","DOI":"10.1007\/s00125-023-06011-5","article-title":"Quantifying beta cell function in the preclinical stages of type 1 diabetes","volume":"66","author":"Galderisi","year":"2023","journal-title":"Diabetologia"},{"key":"10.1016\/j.ecl.2026.04.010_bib24","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1016\/j.trsl.2015.08.010","article-title":"Proinsulin and heat shock protein 90 as biomarkers of beta-cell stress in the early period after onset of type 1 diabetes","volume":"168","author":"Watkins","year":"2016","journal-title":"Transl Res"},{"issue":"9","key":"10.1016\/j.ecl.2026.04.010_bib25","doi-asserted-by":"crossref","first-page":"1519","DOI":"10.2337\/dc15-2849","article-title":"Elevations in the fasting serum Proinsulin-to-C-Peptide ratio precede the onset of type 1 diabetes","volume":"39","author":"Sims","year":"2016","journal-title":"Diabetes Care"},{"issue":"4","key":"10.1016\/j.ecl.2026.04.010_bib26","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1038\/nm.4289","article-title":"Autoimmunity against a defective ribosomal insulin gene product in type 1 diabetes","volume":"23","author":"Kracht","year":"2017","journal-title":"Nat Med"},{"issue":"41","key":"10.1016\/j.ecl.2026.04.010_bib27","doi-asserted-by":"crossref","DOI":"10.1073\/pnas.2107208118","article-title":"Human islet T cells are highly reactive to preproinsulin in type 1 diabetes","volume":"118","author":"Anderson","year":"2021","journal-title":"Proc Natl Acad Sci USA"},{"issue":"1","key":"10.1016\/j.ecl.2026.04.010_bib28","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1007\/s00125-022-05812-4","article-title":"Autoantibody and T cell responses to oxidative post-translationally modified insulin neoantigenic peptides in type 1 diabetes","volume":"66","author":"Strollo","year":"2023","journal-title":"Diabetologia"},{"issue":"9","key":"10.1016\/j.ecl.2026.04.010_bib29","doi-asserted-by":"crossref","first-page":"1830","DOI":"10.2337\/db19-0128","article-title":"Hybrid insulin peptides are autoantigens in type 1 diabetes","volume":"68","author":"Baker","year":"2019","journal-title":"Diabetes"},{"issue":"5","key":"10.1016\/j.ecl.2026.04.010_bib30","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1007\/BF00452061","article-title":"The histopathology of the pancreas in type 1 (insulin-dependent) diabetes mellitus: a 25-year review of deaths in patients under 20 years of age in the United Kingdom","volume":"29","author":"Foulis","year":"1986","journal-title":"Diabetologia"},{"issue":"5","key":"10.1016\/j.ecl.2026.04.010_bib31","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1016\/j.cmet.2006.10.001","article-title":"GLP-1 receptor activation improves beta cell function and survival following induction of endoplasmic reticulum stress","volume":"4","author":"Yusta","year":"2006","journal-title":"Cell Metab"},{"issue":"2","key":"10.1016\/j.ecl.2026.04.010_bib32","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1111\/j.2040-1124.2010.00075.x","article-title":"GLP-1 receptor agonist attenuates endoplasmic reticulum stress-mediated beta-cell damage in Akita mice","volume":"2","author":"Yamane","year":"2011","journal-title":"J Diabetes Investig"},{"issue":"10","key":"10.1016\/j.ecl.2026.04.010_bib33","doi-asserted-by":"crossref","first-page":"3817","DOI":"10.1210\/en.2014-1218","article-title":"GLP-1 analog liraglutide enhances proinsulin processing in pancreatic beta-cells via a PKA-Dependent pathway","volume":"155","author":"Wang","year":"2014","journal-title":"Endocrinology"},{"issue":"4","key":"10.1016\/j.ecl.2026.04.010_bib34","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1056\/NEJM198607243150404","article-title":"Natural course of insulin resistance in type I diabetes","volume":"315","author":"Yki-Jarvinen","year":"1986","journal-title":"N Engl J Med"},{"issue":"11","key":"10.1016\/j.ecl.2026.04.010_bib35","doi-asserted-by":"crossref","first-page":"3168","DOI":"10.1210\/clinem\/dgaf086","article-title":"Metabolic phenotype of stage 1 and stage 2 type 1 diabetes using modeling of beta cell function","volume":"110","author":"Galderisi","year":"2025","journal-title":"J Clin Endocrinol Metab"},{"issue":"3","key":"10.1016\/j.ecl.2026.04.010_bib36","doi-asserted-by":"crossref","first-page":"666","DOI":"10.2337\/dc13-1473","article-title":"Exenatide treatment for 6 months improves insulin sensitivity in adults with type 1 diabetes","volume":"37","author":"Sarkar","year":"2014","journal-title":"Diabetes Care"},{"issue":"11","key":"10.1016\/j.ecl.2026.04.010_bib37","doi-asserted-by":"crossref","first-page":"4905","DOI":"10.1111\/dom.15889","article-title":"Liraglutide enhances insulin secretion and prolongs the remission period in adults with newly diagnosed type 1 diabetes (the NewLira study): a randomized, double-blind, placebo-controlled trial","volume":"26","author":"Dejgaard","year":"2024","journal-title":"Diabetes Obes Metabol"},{"issue":"4","key":"10.1016\/j.ecl.2026.04.010_bib38","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1016\/S2213-8587(21)00019-X","article-title":"Anti-interleukin-21 antibody and liraglutide for the preservation of beta-cell function in adults with recent-onset type 1 diabetes: a randomised, double-blind, placebo-controlled, phase 2 trial","volume":"9","author":"von Herrath","year":"2021","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"4","key":"10.1016\/j.ecl.2026.04.010_bib39","doi-asserted-by":"crossref","first-page":"1054","DOI":"10.1111\/dom.13609","article-title":"Addition of glucagon-like peptide-1 receptor agonist therapy to insulin in C-peptide-positive patients with type 1 diabetes","volume":"21","author":"Kuhadiya","year":"2019","journal-title":"Diabetes Obes Metabol"},{"issue":"3","key":"10.1016\/j.ecl.2026.04.010_bib40","article-title":"Semaglutide treatment in adult-onset autoimmune diabetes: a case study with long-term Follow-Up and periodic evaluation of beta-cell function","volume":"16","author":"Da Porto","year":"2024","journal-title":"Cureus"}],"container-title":["Endocrinology and Metabolism Clinics of North America"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0889852926000319?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0889852926000319?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,7,29]],"date-time":"2026-07-29T23:25:08Z","timestamp":1785367508000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0889852926000319"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9]]},"references-count":39,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2026,9]]}},"alternative-id":["S0889852926000319"],"URL":"https:\/\/doi.org\/10.1016\/j.ecl.2026.04.010","relation":{},"ISSN":["0889-8529"],"issn-type":[{"value":"0889-8529","type":"print"}],"subject":[],"published":{"date-parts":[[2026,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"GLP-1 Receptor Agonists May Reduce Insulin Requirements in New-Onset Type 1 Diabetes","name":"articletitle","label":"Article Title"},{"value":"Endocrinology and Metabolism Clinics of North America","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ecl.2026.04.010","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}